DiaMedica Inc. Receives pre-IND FDA Guidance on DM-71
WINNIPEG, MANITOBA--(Marketwire - May 14, 2008) - DiaMedica Inc. (TSX VENTURE: DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announced that it has received feedback from the U.S. Food and Drug and Administration (FDA) on its pre-IND filing for DM-71, the Company's lead compound.